Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) Hits New 12-Month High on Analyst Upgrade

Key Points

• Senseonics shares reached a 12-month high, trading as high as $13.98 after Barclays raised its price target from $10 to $11; Barclays maintained an Equal Weight rating.
• The company raised its FY 2026 revenue guidance to $68 million–$70 million and expects gross margin above 60%. Third-quarter revenue climbed about 140% year over year to $19.6 million, above analyst estimates.
• Despite stronger sales, Senseonics reported a third-quarter loss of $0.50 per share, slightly worse than the $0.49 consensus estimate. Analysts’ overall rating remains Hold, with a consensus price target of $13.60.

Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS - Get Free Report) hit a new 52-week high during mid-day trading on Tuesday after Barclays raised their price target on the stock from $10.00 to $11.00. Barclays currently has an equal weight rating on the stock. Senseonics Holdings, Inc. Common Stock traded as high as $13.98 and last traded at $12.8120, with a volume of 1,270,989 shares trading hands. The stock had previously closed at $9.80.

Several other research analysts also recently commented on SENS. Stifel Nicolaus reissued a "hold" rating and set a $10.00 price objective (up from $9.00) on shares of Senseonics Holdings, Inc. Common Stock in a report on Tuesday. Weiss Ratings raised Senseonics Holdings, Inc. Common Stock from a "sell (e+)" rating to a "sell (d-)" rating in a report on Wednesday, November 4th. Mizuho decreased their target price on Senseonics Holdings, Inc. Common Stock from $20.00 to $18.00 and set an "outperform" rating on the stock in a research report on Wednesday, July 15th. Raymond James Financial raised Senseonics Holdings, Inc. Common Stock from an "underperform" rating to a "market perform" rating in a research note on Tuesday. Finally, TD Cowen restated a "buy" rating and set a $15.00 price target on shares of Senseonics Holdings, Inc. Common Stock in a report on Tuesday, October 27th. Three investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $13.60.

Insider Activity

In other Senseonics Holdings, Inc. Common Stock news, Director Douglas Roeder purchased 13,953 shares of the firm's stock in a transaction that occurred on Wednesday, August 19th. The stock was purchased at an average cost of $8.98 per share, with a total value of $125,297.94. Following the purchase, the director owned 171,191 shares of the company's stock, valued at approximately $1,537,295.18. The trade was a 8.87% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 4.70% of the company's stock.

Key Headlines Impacting Senseonics Holdings, Inc. Common Stock

Here are the key news stories impacting Senseonics Holdings, Inc. Common Stock this week:

• Positive Sentiment: Senseonics raised its FY 2026 revenue guidance to $68 million–$70 million, up from $62 million–$66 million and above the $64.2 million consensus estimate. It also lifted its full-year gross-margin outlook to more than 60%. Third-quarter 2026 results
• Positive Sentiment: Third-quarter revenue was about $19.6 million, up approximately 140% year over year, and exceeded analyst revenue estimates, highlighting strong sales growth. Q3 results and revenue estimates
• Positive Sentiment: HC Wainwright reaffirmed its Buy rating and set a $14 price target. Raymond James also upgraded SENS, moving its rating from Underperform to Market Perform. HC Wainwright rating
• Negative Sentiment: The company reported a third-quarter loss of $0.50 per share, slightly worse than the $0.49 consensus loss and wider than the $0.43 loss a year earlier. Quarterly earnings results

Hedge Funds Weigh In On Senseonics Holdings, Inc. Common Stock

A number of hedge funds and other institutional investors have recently made changes to their positions in SENS. StoneX Group Inc. purchased a new position in Senseonics Holdings, Inc. Common Stock during the third quarter valued at approximately $128,000. Traynor Capital Management Inc. acquired a new position in shares of Senseonics Holdings, Inc. Common Stock during the third quarter worth $152,000. State of Wyoming lifted its holdings in shares of Senseonics Holdings, Inc. Common Stock by 27.2% during the 3rd quarter. State of Wyoming now owns 14,940 shares of the company's stock valued at $152,000 after purchasing an additional 3,199 shares during the last quarter. Integrated Wealth Concepts LLC purchased a new stake in shares of Senseonics Holdings, Inc. Common Stock during the 2nd quarter valued at $36,000. Finally, Readystate Asset Management LP acquired a new stake in shares of Senseonics Holdings, Inc. Common Stock in the 2nd quarter worth $574,000. Institutional investors own 12.36% of the company's stock.

Senseonics Holdings, Inc. Common Stock Price Performance

The stock has a 50-day moving average price of $9.12 and a two-hundred day moving average price of $7.26. The company has a current ratio of 6.74, a quick ratio of 6.40 and a debt-to-equity ratio of 0.62. The stock has a market cap of $521.04 million, a price-to-earnings ratio of -5.76 and a beta of 1.04.

Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS - Get Free Report) last released its quarterly earnings results on Monday, November 9th. The company reported ($0.50) EPS for the quarter, missing analysts' consensus estimates of ($0.49) by ($0.01). The business had revenue of $19.56 million during the quarter. Senseonics Holdings, Inc. Common Stock had a negative net margin of 225.09% and a negative return on equity of 165.80%. As a group, equities research analysts forecast that Senseonics Holdings, Inc. Common Stock will post -2.31 EPS for the current year.

Senseonics Holdings, Inc. Common Stock Company Profile

Senseonics Holdings, Inc is a medical technology company focused on developing and commercializing long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes. Its CGM technology is designed to measure glucose levels continuously through a small sensor inserted under the skin, with readings transmitted to an external smart transmitter and mobile application.

The company's primary product is the Eversense CGM system. Unlike many conventional CGM systems that use an externally worn sensor, Eversense uses an implantable sensor and a removable, rechargeable transmitter worn over the sensor site.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.